Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2024 | Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD

Mohamad Mohty • 17 Apr 2024

EBMT 2024

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into the challenges of treating steroid-refractory acute and chronic graft-versus-host disease (GvHD) in patients undergoing allogeneic stem cell transplantation (alloSCT). Prof. Mohty first highlights novel agents being explored for acute GvHD, including the JAK inhibitor ruxolitinib, and MaaT013, a microbiome modulating therapy. Following this, Prof. Mohty discusses the promising results observed with the ROCK2 inhibitor belumosudil for patients with chronic GvHD. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.